G-Protein Coupled Receptors Market Size, Share & Growth Graph by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global G-Protein Coupled Receptors Market Size Analysis

Global G-Protein Coupled Receptors Market Introduction
By Component
1. Introduction
  1. Component By Value
2. Reagents & Kits
  1. By Value
3. Cell Lines
  1. By Value
4. Assay Platforms
  1. By Value
5. Detection Instruments
  1. By Value
6. Services
  1. By Value
By Assay Type
1. Introduction
  1. Assay Type By Value
2. Calcium Level Detection Assays
  1. By Value
3. Radioligand Binding & GTPS Assays
  1. By Value
4. cAMP & cGMP Assays
  1. By Value
5. β-Arrestin Functional Assays
  1. By Value
6. Reporter Gene Assays
  1. By Value
7. Label-free Impedance Assays
  1. By Value
8. Other Assay Types
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Cardiovascular System
  1. By Value
3. Central Nervous System
  1. By Value
4. Oncology
  1. By Value
5. Metabolic Disorders
  1. By Value
6. Respiratory Diseases
  1. By Value
7. Other Therapeutic Areas
  1. By Value

North America Market Analysis

Introduction
By Component
1. Introduction
  1. Component By Value
2. Reagents & Kits
  1. By Value
3. Cell Lines
  1. By Value
4. Assay Platforms
  1. By Value
5. Detection Instruments
  1. By Value
6. Services
  1. By Value
By Assay Type
1. Introduction
  1. Assay Type By Value
2. Calcium Level Detection Assays
  1. By Value
3. Radioligand Binding & GTPS Assays
  1. By Value
4. cAMP & cGMP Assays
  1. By Value
5. β-Arrestin Functional Assays
  1. By Value
6. Reporter Gene Assays
  1. By Value
7. Label-free Impedance Assays
  1. By Value
8. Other Assay Types
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Cardiovascular System
  1. By Value
3. Central Nervous System
  1. By Value
4. Oncology
  1. By Value
5. Metabolic Disorders
  1. By Value
6. Respiratory Diseases
  1. By Value
7. Other Therapeutic Areas
  1. By Value
U.S.
1. By Component
  1. Introduction
    1. Component By Value
  2. Reagents & Kits
    1. By Value
  3. Cell Lines
    1. By Value
  4. Assay Platforms
    1. By Value
  5. Detection Instruments
    1. By Value
  6. Services
    1. By Value
2. By Assay Type
  1. Introduction
    1. Assay Type By Value
  2. Calcium Level Detection Assays
    1. By Value
  3. Radioligand Binding & GTPS Assays
    1. By Value
  4. cAMP & cGMP Assays
    1. By Value
  5. β-Arrestin Functional Assays
    1. By Value
  6. Reporter Gene Assays
    1. By Value
  7. Label-free Impedance Assays
    1. By Value
  8. Other Assay Types
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Cardiovascular System
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Oncology
    1. By Value
  5. Metabolic Disorders
    1. By Value
  6. Respiratory Diseases
    1. By Value
  7. Other Therapeutic Areas
    1. By Value
Canada

Europe Market Analysis

Introduction
By Component
1. Introduction
  1. Component By Value
2. Reagents & Kits
  1. By Value
3. Cell Lines
  1. By Value
4. Assay Platforms
  1. By Value
5. Detection Instruments
  1. By Value
6. Services
  1. By Value
By Assay Type
1. Introduction
  1. Assay Type By Value
2. Calcium Level Detection Assays
  1. By Value
3. Radioligand Binding & GTPS Assays
  1. By Value
4. cAMP & cGMP Assays
  1. By Value
5. β-Arrestin Functional Assays
  1. By Value
6. Reporter Gene Assays
  1. By Value
7. Label-free Impedance Assays
  1. By Value
8. Other Assay Types
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Cardiovascular System
  1. By Value
3. Central Nervous System
  1. By Value
4. Oncology
  1. By Value
5. Metabolic Disorders
  1. By Value
6. Respiratory Diseases
  1. By Value
7. Other Therapeutic Areas
  1. By Value
U.K.
1. By Component
  1. Introduction
    1. Component By Value
  2. Reagents & Kits
    1. By Value
  3. Cell Lines
    1. By Value
  4. Assay Platforms
    1. By Value
  5. Detection Instruments
    1. By Value
  6. Services
    1. By Value
2. By Assay Type
  1. Introduction
    1. Assay Type By Value
  2. Calcium Level Detection Assays
    1. By Value
  3. Radioligand Binding & GTPS Assays
    1. By Value
  4. cAMP & cGMP Assays
    1. By Value
  5. β-Arrestin Functional Assays
    1. By Value
  6. Reporter Gene Assays
    1. By Value
  7. Label-free Impedance Assays
    1. By Value
  8. Other Assay Types
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Cardiovascular System
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Oncology
    1. By Value
  5. Metabolic Disorders
    1. By Value
  6. Respiratory Diseases
    1. By Value
  7. Other Therapeutic Areas
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Component
1. Introduction
  1. Component By Value
2. Reagents & Kits
  1. By Value
3. Cell Lines
  1. By Value
4. Assay Platforms
  1. By Value
5. Detection Instruments
  1. By Value
6. Services
  1. By Value
By Assay Type
1. Introduction
  1. Assay Type By Value
2. Calcium Level Detection Assays
  1. By Value
3. Radioligand Binding & GTPS Assays
  1. By Value
4. cAMP & cGMP Assays
  1. By Value
5. β-Arrestin Functional Assays
  1. By Value
6. Reporter Gene Assays
  1. By Value
7. Label-free Impedance Assays
  1. By Value
8. Other Assay Types
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Cardiovascular System
  1. By Value
3. Central Nervous System
  1. By Value
4. Oncology
  1. By Value
5. Metabolic Disorders
  1. By Value
6. Respiratory Diseases
  1. By Value
7. Other Therapeutic Areas
  1. By Value
China
1. By Component
  1. Introduction
    1. Component By Value
  2. Reagents & Kits
    1. By Value
  3. Cell Lines
    1. By Value
  4. Assay Platforms
    1. By Value
  5. Detection Instruments
    1. By Value
  6. Services
    1. By Value
2. By Assay Type
  1. Introduction
    1. Assay Type By Value
  2. Calcium Level Detection Assays
    1. By Value
  3. Radioligand Binding & GTPS Assays
    1. By Value
  4. cAMP & cGMP Assays
    1. By Value
  5. β-Arrestin Functional Assays
    1. By Value
  6. Reporter Gene Assays
    1. By Value
  7. Label-free Impedance Assays
    1. By Value
  8. Other Assay Types
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Cardiovascular System
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Oncology
    1. By Value
  5. Metabolic Disorders
    1. By Value
  6. Respiratory Diseases
    1. By Value
  7. Other Therapeutic Areas
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Component
1. Introduction
  1. Component By Value
2. Reagents & Kits
  1. By Value
3. Cell Lines
  1. By Value
4. Assay Platforms
  1. By Value
5. Detection Instruments
  1. By Value
6. Services
  1. By Value
By Assay Type
1. Introduction
  1. Assay Type By Value
2. Calcium Level Detection Assays
  1. By Value
3. Radioligand Binding & GTPS Assays
  1. By Value
4. cAMP & cGMP Assays
  1. By Value
5. β-Arrestin Functional Assays
  1. By Value
6. Reporter Gene Assays
  1. By Value
7. Label-free Impedance Assays
  1. By Value
8. Other Assay Types
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Cardiovascular System
  1. By Value
3. Central Nervous System
  1. By Value
4. Oncology
  1. By Value
5. Metabolic Disorders
  1. By Value
6. Respiratory Diseases
  1. By Value
7. Other Therapeutic Areas
  1. By Value
UAE
1. By Component
  1. Introduction
    1. Component By Value
  2. Reagents & Kits
    1. By Value
  3. Cell Lines
    1. By Value
  4. Assay Platforms
    1. By Value
  5. Detection Instruments
    1. By Value
  6. Services
    1. By Value
2. By Assay Type
  1. Introduction
    1. Assay Type By Value
  2. Calcium Level Detection Assays
    1. By Value
  3. Radioligand Binding & GTPS Assays
    1. By Value
  4. cAMP & cGMP Assays
    1. By Value
  5. β-Arrestin Functional Assays
    1. By Value
  6. Reporter Gene Assays
    1. By Value
  7. Label-free Impedance Assays
    1. By Value
  8. Other Assay Types
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Cardiovascular System
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Oncology
    1. By Value
  5. Metabolic Disorders
    1. By Value
  6. Respiratory Diseases
    1. By Value
  7. Other Therapeutic Areas
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Component
1. Introduction
  1. Component By Value
2. Reagents & Kits
  1. By Value
3. Cell Lines
  1. By Value
4. Assay Platforms
  1. By Value
5. Detection Instruments
  1. By Value
6. Services
  1. By Value
By Assay Type
1. Introduction
  1. Assay Type By Value
2. Calcium Level Detection Assays
  1. By Value
3. Radioligand Binding & GTPS Assays
  1. By Value
4. cAMP & cGMP Assays
  1. By Value
5. β-Arrestin Functional Assays
  1. By Value
6. Reporter Gene Assays
  1. By Value
7. Label-free Impedance Assays
  1. By Value
8. Other Assay Types
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Cardiovascular System
  1. By Value
3. Central Nervous System
  1. By Value
4. Oncology
  1. By Value
5. Metabolic Disorders
  1. By Value
6. Respiratory Diseases
  1. By Value
7. Other Therapeutic Areas
  1. By Value
Brazil
1. By Component
  1. Introduction
    1. Component By Value
  2. Reagents & Kits
    1. By Value
  3. Cell Lines
    1. By Value
  4. Assay Platforms
    1. By Value
  5. Detection Instruments
    1. By Value
  6. Services
    1. By Value
2. By Assay Type
  1. Introduction
    1. Assay Type By Value
  2. Calcium Level Detection Assays
    1. By Value
  3. Radioligand Binding & GTPS Assays
    1. By Value
  4. cAMP & cGMP Assays
    1. By Value
  5. β-Arrestin Functional Assays
    1. By Value
  6. Reporter Gene Assays
    1. By Value
  7. Label-free Impedance Assays
    1. By Value
  8. Other Assay Types
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Cardiovascular System
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Oncology
    1. By Value
  5. Metabolic Disorders
    1. By Value
  6. Respiratory Diseases
    1. By Value
  7. Other Therapeutic Areas
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

G-Protein Coupled Receptors Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Abcam plc
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Addex Therapeutics Ltd.
Becton, Dickinson and Company
BioInvenu Inc.
Bio-Rad Laboratories Inc.
BMG Labtech GmbH
Charles River Laboratories
Cisbio
Corning Incorporated
Danaher
Enzo Biochem Inc.
Eurofins Scientific SE
4.13 Evotec SE
HD Biosciences Co., Ltd.
ION Biosciences
Luminex Corporation
Merck KGaA

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment